Supporting Information

Facile access to benzofuran-fused tetrahydropyridines via catalytic asymmetric [4 + 2] cycloaddition of aurone-derived 1azadienes with 3-vinylindoles

Wai Lean Koay,^{ab} Guang-Jian Mei,^{*a} and Yixin Lu^{*abc}

a. Department of Chemistry, National University of Singapore, 3 Science Drive 3, 117543, Singapore. E-mail: mgjx1x2x3@163.com; chmlyx@nus.edu.sg.

b. NUS Graduate School for Integrative Sciences & Engineering (NGS), National University of Singapore, University Hall, Tan Chin Tuan Wing #04-02, 21 Lower Kent Ridge Road, Singapore, 119077, Singapore
c. Joint School of National University of Singapore and Tianjin University, International Campus of Tianjin University, Binhai New City, Fuzhou, Fujian, 350207, China

Supporting Information

A.	General information	S03
B.	Representative Procedures	S04
C.	Analytical Data and HPLC Chromatograms of the Products	S06
D.	X-Ray Crystallographic Analysis and Determination of the Absolute Configurations of Product 3b	S35
E.	References	S36
F.	¹ H and ¹³ C NMR Spectra of the Products	S37

A. General Information

Unless otherwise specified, all reactions were conducted under an inert atmosphere and anhydrous conditions. All the solvents were purified according to the standard procedures. All chemicals which are commercially available were employed without further purification. Thin-layer chromatography (TLC) was performed on silica gel plates (60F-254) using UV-light (254 and 365 nm). Flash chromatography was conducted on silica gel (200-300 mesh). ¹H and ¹³C NMR spectra were recorded at ambient temperature in CDCl₃ on a Bruker AMX500 (500 MHz) or AMX400 (400 MHz) spectrometer. Chemical shifts were reported in parts per million (ppm). The data are reported as follows: for ¹H NMR, chemical shift in ppm from tetramethylsilane with the solvent as internal standard (CDCl₃ δ 7.26 ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet or overlap of non-equivalent resonances), integration; for ¹³C NMR, chemical shift in ppm from tetramethylsilane with the solvent as internal indicator (CDCl₃ & 77.1 ppm), multiplicity with respect to protons. All high-resolution mass spectra were performed by the MS service at the chemistry department, National University of Singapore, and were obtained on a Finnigan/MAT 95XL-T spectrometer to be given in m/z. Optical rotations were measured using an Anton Paar MCP-100 digital polarimeter using a 1 cm glass cell. Enantiomeric excesses were determined by HPLC analysis on a chiral stationary phase using CHIRALPAK® columns (IE, ID & IC) eluting with hexane/isopropanol mixtures as indicated. Aurone-derived 1-azadienes 1^1 and 3-vinylindoles 2^2 were synthesized according to literature-reported procedures respectively.

B. Representative Procedures

General Procedure for chiral phosphoric acid catalyzed dearomative [3 + 2] cycloaddition reaction of α naphthols with azoalkenes:



To a stirring anhydrous $Et_2O:CH_2Cl_2$ (2:1) solution (1 ml) of aurone-derived 1-azadienes **1** (0.1 mmol) and 3vinylindoles **2** (0.18 mmol) was added 5Å MS (100 mg) and CPA **4b** (1 mol%) at rt. The reaction mixture was stirred until completion of reaction (as monitored by TLC). After which, the mixture was filtered and the solvent was removed under reduced pressure and the residue was purified by flash column chromatography on silica gel (Hexane: $CH_2Cl_2 = 2:1$) to afford cycloadducts **3**.





^aReaction conditions: **1a** (0.1 mmol), **2a** (0.18 mmol), and catalyst **4** (1 mol%), 5Å MS (100 mg) in the solvent specified (1 mL) at RT for 20 h. ^bThe diastereomeric ratio (dr) value was determined by crude ¹H NMR. ^cIsolated yield. ^dThe *ee* value was determined by HPLC analysis using a chiral stationary phase. ^eEt₂O:CH₂Cl₂ = 2:1. Synthesis of 3a at a gram-scale:



To a stirring anhydrous $Et_2O:CH_2Cl_2$ (2:1) solution (15 ml) of aurone-derived 1-azadienes **1a** (3 mmol) and 3vinylindoles **2a** (5.4 mmol) was added 5Å MS (3 g) and CPA **4b** (1 mol%) at rt. The reaction mixture was stirred until completion of reaction (as monitored by TLC). Then, the reaction mixture was vacuum filtered through Celite and water was added to the filtrate followed by extraction with AcOEt (2 × 20 mL). The combined organic layer was washed with brine, separated, dried over Na₂SO₄ and filtered. The solvent was then removed under reduced pressure and the residue was purified by flash column chromatography on silica gel (Hexane: $CH_2Cl_2 =$ 2:1) to afford product **3a** (1.3 g) in 87% yield with 92% *ee*.

Further elaborations of 3a:



For **3a-I**: To a stirring anhydrous CH_2Cl_2 solution (1 ml) of **3a** (0.1 mmol) was added Et_3N (0.2 mmol) and Boc_2O (0.15 mmol) at rt. The reaction mixture was stirred until completion of reaction (as monitored by TLC). Then, the reaction was quenched by adding the NH₄Cl aqueous solution followed by extraction with AcOEt (2 × 2 mL). The combined organic layer was washed with brine, separated, dried over Na₂SO₄ and filtered. The solvent was then removed under reduced pressure and the residue was purified by flash column chromatography on silica gel (Hexane: $CH_2Cl_2 = 2:1$) to afford product **3a-I** (58 mg) in 96% yield.

For **3a-II**: To a stirring anhydrous toluene solution (1 ml) of **3a** (0.1 mmol) was added Red-Al (1 mmol) at-20 °C. The reaction mixture was stirred until completion of reaction (as monitored by TLC). Then, the reaction was quenched by adding the NH₄Cl aqueous solution followed by extraction with AcOEt (2×2 mL). The combined organic layer was washed with brine, separated, dried over Na₂SO₄ and filtered. The solvent was then removed under reduced pressure and the residue was purified by flash column chromatography on basic alumina (Hexane: AcOEt = 8:1) to afford product **3a-II** (48 mg) in 93% yield

C. Analytical Data and HPLC Chromatograms of the Products

(2S, 3R, 4R)-2-(1H-indol-3-yl)-1-(methylsulfonyl)-3,4-diphenyl-1,2,3,4-tetrahydrobenzofuro[3,2-b]pyridine **3a**



Yellowish oil; isolated yield = 98%; $[a]_D^{25} = -55.2$ (c 1.0, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.07 – 8.01 (m, 1H), 7.90 (s, 1H), 7.58 – 7.31 (m, 4H), 7.25 – 7.13 (m, 5H), 7.11 – 6.88 (m, 5H), 6.85 – 6.73 (m, 3H), 5.86 (d, J = 7.1 Hz, 1H), 4.58 (d, J = 5.6 Hz, 1H), 4.43 – 4.40 (m, 1H), 2.35 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 154.0, 146.3, 141.8, 139.3, 135.9, 128.6, 128.0, 127.9, 127.8, 127.1, 126.3, 126.1, 124.9, 124.6, 123.3, 123.1, 122.1, 121.4, 120.0, 119.9, 118.5, 112.0, 111.8, 111.3, 61.4, 51.5, 45.7, 41.6. HRMS (ESI) m/z calcd for C₃₂H₂₆N₂O₃S [M - H]⁻ = 517.1591, found = 517.1589; HRMS (ESI) m/z calcd for C₃₂H₂₅FN₂O₃S [M - H]⁻ = 535.1497, found = 535.1502; the *ee* value was 93%, t_R (major) = 10.6 min, t_R (minor) = 20.8 min (Chiralpak IE, $\lambda = 254$ nm, 20% *i*-PrOH/Hexane, flow rate = 1.0 mL/min).



Racemic **3a**

Enantioenriched 3a

<u>b]pyridine</u> **3b**



Yellowish oil; isolated yield = 93%; $[a]_D^{25} = -156$ (c 0.5, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 8.17 – 8.04 (m, 1H), 7.88 (s, 1H), 7.51 – 7.43 (m, 1H), 7.41 – 7.30 (m, 2H), 7.30 – 7.17 (m, 5H), 7.15 – 7.12 (m, 1H), 7.07 – 7.04 (m, 1H), 6.94 – 6.81 (m, 3H), 6.81 – 6.78 (m, 1H), 6.73 – 6.66 (m, 2H), 5.84 (d, *J* = 6.2 Hz, 1H), 4.62 (d, *J* = 4.8 Hz, 1H), 4.37 – 4.34 (m, 1H), 2.33 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 157.7 (d, *J* = 234 Hz), 154.1, 145.4, 141.7, 139.4, 132.5, 128.8, 128.0, 127.8, 127.7, 127.4, 126.4, 126.2, 124.8, 123.3, 122.9, 121.6, 119.8, 112.0, 111.9, 111.8, 110.5 (d, *J* = 26 Hz), 103.7 (d, *J* = 24 Hz), 61.3, 50.9, 44.6, 41.2; HRMS (ESI) m/z calcd for C₃₂H₂₅FN₂O₃S [M - H]⁻ = 535.1497, found = 535.1502; the *ee* value was 99%, t_R (major) = 8.0 min, t_R (minor) = 18.9 min (Chiralpak IE, λ = 254 nm, 20% *i*-PrOH/Hexane, flow rate = 1.0 mL/min).



Racemic 3b

Enantioenriched 3b

<u>b]pyridine</u> 3c



Yellowish oil; isolated yield = 92%; $[a]_D^{25} = -171$ (c 0.5, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 8.19 – 8.13 (m, 1H), 7.93 (s, 1H), 7.52 – 7.43 (m, 1H), 7.43 (s, 1H), 7.41 – 7.27 (m, 2H), 7.30 – 7.15 (m, 4H), 7.07 – 6.96 (m, 2H), 6.93 – 6.80 (m, 4H), 6.71 – 6.64 (m, 2H), 5.86 (d, *J* = 6.2 Hz, 1H), 4.64 (d, *J* = 4.6 Hz, 1H), 4.39 – 4.36 (m, 1H), 2.30 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 154.1, 145.2, 141.6, 139.4, 134.4, 128.8, 128.0, 127.7, 127.6, 127.4, 126.9, 126.1, 125.9, 125.4, 124.7, 123.2, 122.7, 122.3, 121.6, 119.7, 118.1, 112.4, 112.2, 111.8, 61.2, 50.7, 44.3, 41.1; HRMS (ESI) m/z calcd for C₃₂H₂₅ClN₂O₃S [M - H]⁻ = 551.1202, found = 551.1204; the *ee* value was 99%, t_R (major) = 6.9 min, t_R (minor) = 8.8min (Chiralpak IE, λ = 254 nm, 20% *i*-PrOH/Hexane, flow rate = 1.0 mL/min).



Racemic 3c

Enantioenriched 3c

b]pyridine 3d



Yellowish oil; isolated yield = 84%; $[a]_D^{25} = -188$ (c 1.0, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.22 - 8.16 (m, 1H), 7.98 (s, 1H), 7.61 (s, 1H), 7.53 - 7.48 (m, 1H), 7.43 - 7.34 (m, 2H), 7.33 - 7.21 (m, 3H), 7.16 - 7.14 (m, 1H), 7.02 (d, *J* = 8.6 Hz, 1H), 6.95 - 6.83 (m, 5H), 6.71 (d, *J* = 7.0 Hz, 2H), 5.89 (d, *J* = 6.0 Hz, 1H), 4.67 (d, *J* = 4.6 Hz, 1H), 4.43 - 4.37 (m, 1H), 2.32 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 154.1, 145.3, 141.6, 139.4, 134.7, 128.8, 128.0, 127.8, 127.7, 127.6, 127.4, 126.2, 125.8, 124.9, 124.8, 123.3, 122.8, 121.6, 121.2, 119.7, 113.1, 112.7, 112.3, 111.9, 61.3, 50.7, 44.4, 41.1; HRMS (ESI) m/z calcd for C₃₂H₂₅BrN₂O₃S [M - H]⁻ = 595.0696, found = 595.0682; the *ee* value was 91%, t_R (major) = 6.8 min, t_R (minor) = 7.7 min (Chiralpak IE, λ = 254 nm, 20% *i*-PrOH/Hexane, flow rate = 1.0 mL/min).



Racemic 3d

Enantioenriched 3d

<u>b]pyridine</u> 3e



Yellowish oil; isolated yield = 84%; $[a]_D^{25} = -128$ (c 0.5, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 8.18 – 8.11 (m, 1H), 7.83 (s, 1H), 7.50 – 7.45 (m, 1H), 7.43 – 7.30 (m, 3H), 7.25 – 7.21 (m, 4H), 6.90 – 6.63 (m, 8H), 5.89 (d, J = 6.0 Hz, 1H), 4.64 (d, J = 4.6 Hz, 1H), 4.40 – 4.33 (m, 1H), 2.34 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 159.8 (d, J = 237 Hz), 154.1, 145.2, 141.8, 139.5, 136.2, 136.1, 128.8, 128.0, 127.8, 127.7, 127.4, 126.2, 124.8, 124.7, 123.3, 122.8, 122.4, 121.6, 119.8, 119.4, 119.3, 113.0, 111.9, 108.6 (d, J = 25 Hz), 97.5 (d, J = 26 Hz), 61.4, 51.2, 44.3, 41.1; HRMS (ESI) m/z calcd for C₃₂H₂₅FN₂O₃S [M - H]⁻ = 535.1497, found = 535.1496; the *ee* value was 88%, t_R (major) = 8.7 min, t_R (minor) = 16.2 min (Chiralpak IE, $\lambda = 254$ nm, 20% *i*-PrOH/Hexane, flow rate = 1.0 mL/min).



Racemic 3e

Enantioenriched 3e

<u>b]pyridine 3f</u>



Yellowish oil; isolated yield = 92%; $[a]_D^{25} = -100$ (c 1.0, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 8.16 – 8.10 (m, 1H), 7.87 (s, 1H), 7.52 – 7.43 (m, 1H), 7.41 – 7.30 (m, 3H), 7.30 – 7.16 (m, 4H), 7.14 – 7.13 (m, 1H), 6.96 – 6.94 (m, 1H), 6.89 – 6.88 (m, 3H), 6.81 – 6.80 (m, 1H), 6.69 – 6.67 (m, 2H), 5.87 (d, *J* = 5.5 Hz, 1H), 4.63 (d, *J* = 4.8 Hz, 1H), 4.38 – 4.31 (m, 1H), 2.33 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 154.1, 145.3, 141.6, 139.3, 136.4, 128.8, 128.0, 127.8, 127.4, 126.3, 125.1, 124.8, 124.4, 123.3, 122.8, 121.6, 120.6, 119.7, 119.5, 113.0, 111.9, 111.2, 61.3, 51.2, 44.4, 41.1; HRMS (ESI) m/z calcd for C₃₂H₂₅ClN₂O₃S [M - H]⁻ = 551.1202, found = 551.1197; the *ee* value was 92%, t_R (major) = 8.7 min, t_R (minor) = 17.6 min (Chiralpak IE, λ = 254 nm, 20% *i*-PrOH/Hexane, flow rate = 1.0 mL/min).





Enantioenriched $\mathbf{3f}$

b]pyridine 3g



Yellowish oil; isolated yield = 97%; $[a]_D^{25} = -131$ (c 2, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.17 – 8.15 (m, 1H), 8.05 (s, 1H), 7.52 – 7.45 (m, 1H), 7.41 – 7.32 (m, 2H), 7.32 – 7.18 (m, 5H), 6.94 – 6.83 (m, 5H), 6.80 – 6.76 (m, 1H), 6.70 – 6.67 (m, 2H), 5.91 (d, *J* = 6.1 Hz, 1H), 4.65 (d, *J* = 4.6 Hz, 1H), 4.42 – 4.36 (m, 1H), 2.35 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 154.1, 149.3 (d, *J* = 243 Hz), 145.2, 141.7, 139.4, 129.4 (d, *J* = 5 Hz), 128.8, 128.0, 127.8, 127.6, 127.4, 126.2, 125.0, 124.8, 124.5 (d, *J* = 14 Hz), 123.2, 122.7, 121.6, 120.2, 120.1, 119.7, 114.5 (d, *J* = 4 Hz), 113.7, 111.9, 106.9 (d, *J* = 16 Hz), 61.3, 51.0, 44.3, 41.1; HRMS (ESI) m/z calcd for C₃₂H₂₅FN₂O₃S [M - H]⁻ = 535.1497, found = 535.1500; the *ee* value was 95%, t_R (major) = 8.6 min, t_R (minor) = 12.4 min (Chiralpak IE, λ = 254 nm, 20% *i*-PrOH/Hexane, flow rate = 1.0 mL/min).



Racemic 3g

Enantioenriched 3g

<u>b]pyridine</u> 3h



Yellowish oil; isolated yield = 98%; $[a]_D^{25} = -158$ (c 2.0, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.24 – 8.23 (m, 1H), 7.91 (s, 1H), 7.52 – 7.42 (m, 2H), 7.41 – 7.18 (m, 7H), 6.88 – 6.77 (m, 4H), 6.64 – 6.58 (m, 2H), 5.87 (d, J = 6.2 Hz, 1H), 4.68 (d, J = 3.8 Hz, 1H), 4.36 – 4.29 (m, 1H), 2.28 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 154.2, 144.5, 141.5, 139.5, 135.0, 129.0, 128.0, 127.7, 127.6, 126.1, 125.8, 125.3, 125.0, 123.7, 123.4, 122.4, 121.7, 119.8, 119.5, 113.1, 112.6, 111.9, 61.3, 50.5, 43.3, 40.7; HRMS (ESI) m/z calcd for C₃₂H₂₄Cl₂N₂O₃S [M - H]⁻ = 585.0812, found = 585.0811; the *ee* value was 94%, t_R (major) = 6.6 min, t_R (minor) = 7.5 min (Chiralpak IE, $\lambda = 254$ nm, 20% *i*-PrOH/Hexane, flow rate = 1.0 mL/min).



(2S, 3R, 4R) - 2 - (2 - methyl - 1H - indol - 3 - yl) - 1 - (methyl sulfonyl) - 3, 4 - diphenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yl) - 1 - (methyl sulfonyl) - 3, 4 - diphenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yl) - 1 - (methyl sulfonyl) - 3, 4 - diphenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yl) - 1 - (methyl sulfonyl) - 3, 4 - diphenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yl) - 1 - (methyl sulfonyl) - 3, 4 - diphenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yl) - 1 - (methyl sulfonyl) - 3, 4 - diphenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yl) - 1 - (methyl sulfonyl) - 3, 4 - diphenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yl) - 1 - (methyl sulfonyl) - 3, 4 - diphenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yl) - 1 - (methyl sulfonyl) - 3, 4 - diphenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yl) - 1 - (methyl sulfonyl) - 3, 4 - diphenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yl) - 1 - (methyl sulfonyl) - 3, 4 - diphenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yl) - 1 - (methyl sulfonyl) - 3, 4 - diphenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yl) - 1 - (methyl sulfonyl) - 3, 4 - diphenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yl) - 1 - (methyl sulfonyl) - 3, 4 - diphenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yl) - 1 - (methyl sulfonyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yl) - 1 - (methyl sulfonyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yl) - 1 - (methyl sulfonyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yl) - 1 - (methyl sulfonyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yl) - 1 - (methyl sulfonyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yl) - 1 - (methyl sulfonyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yl) - 1 - (methyl sulfonyl - 1, 2, 3 - tetrahydrobenzofuro [3, 2 - yl) - 1 - (methyl sulfonyl - 1, 2, 3 - tetrahydrobenzofuro [3, 2 - yl) - 1 - (methyl sulfonyl - 1, 2, 3 - tetrahydrobenzofuro [3, 2 - yl) - 1 - (methyl sulfonyl - 1, 2, 3 - tetrahydrobenzofuro [3, 2 - yl) - 1 - (methyl sulfonyl - 1, 2 - tetrahydrobenzofuro [3,

b]pyridine 3i



Brownish oil; isolated yield = 97%; $[a]_D^{25} = -12$ (c 1.0, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.74 – 7.69 (m, 1H), 7.62 (s, 1H), 7.46 – 7.35 (m, 2H), 7.34 – 7.21 (m, 2H), 7.20 – 6.94 (m, 10H), 6.82 – 6.77 (m, 2H), 5.60 (d, J = 11.0 Hz, 1H), 4.69 (d, J = 11.0 Hz, 1H), 3.89 – 3.84 (m, 1H), 2.61 (s, 3H), 1.77 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 154.0, 146.6, 139.0, 136.8, 135.3, 134.2, 129.1, 128.7, 128.3, 128.1, 127.2, 127.0, 126.3, 124.1, 123.7, 122.9, 121.3, 121.1, 120.0, 118.9, 118.7, 111.9, 110.8, 108.8, 61.1, 57.7, 46.1, 41.9, 11.2; HRMS (ESI) m/z calcd for C₃₃H₂₈N₂O₃S [M - H]⁻ = 531.1748, found = 531.1751; the *ee* value was 63%, t_R (major) = 7.1 min, t_R (minor) = 14.0 min (Chiralpak IE, $\lambda = 254$ nm, 20% *i*-PrOH/Hexane, flow rate = 1.0 mL/min).



Racemic 3i



tetrahydrobenzofuro[3,2-b]pyridine 3j



Yellowish oil; isolated yield = 94%; $[a]_D^{25} = -142$ (c 1.0, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.01 (s, 1H), 7.92 (s, 1H), 7.69 – 7.67 (m, 1H), 7.48 – 7.46 (m, 1H), 7.37 – 7.35 (m, 3H), 7.17 – 7.06 (m, 4H), 7.01 – 6.90 (m, 5H), 6.73 (s, 2H), 5.94 (s, 1H), 4.97 (s, 1H), 4.58 (s, 1H), 2.50 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 154.1, 139.2, 135.9, 134.4, 130.0, 128.5, 127.9, 127.3, 126.4, 124.7, 123.2, 122.2, 121.4, 120.5, 120.0, 119.1, 111.9, 111.1, 59.4, 45.7, 42.1, 29.8; HRMS (ESI) m/z calcd for C₃₂H₂₅ClN₂O₃S [M - H]⁻ = 551.1202, found = 551.1191; the *ee* value was 90%, t_R (major) = 8.6 min, t_R (minor) = 28.8 min (Chiralpak IE, λ = 254 nm, 20% *i*-PrOH/Hexane, flow rate = 1.0 mL/min).





Enantioenriched 3j

tetrahydrobenzofuro[3,2-b]pyridine 3k



Yellowish oil; isolated yield = 92%; $[a]_D^{25} = -105$ (c 0.5, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.99 – 7.91 (m, 2H), 7.56 – 7.54 (m, 1H), 7.46 – 7.44 (m, 1H), 7.36 – 7.33 (m, 2H), 7.23 – 7.22 (m, 1H), 7.14 – 6.97 (m, 9H), 6.86 – 6.80 (m, 2H), 5.75 (d, J = 7.9 Hz, 1H), 4.48 (d, J = 6.6 Hz, 1H), 4.40 – 4.33 (m, 1H), 2.44 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 154.1, 143.9, 138.9, 135.8, 134.4, 130.0, 128.2, 128.1, 127.4, 126.8, 126.3, 125.4, 124.7, 123.6, 123.2, 122.5, 121.2, 120.2, 118.5, 111.9, 111.5, 111.3, 60.9, 52.1, 46.8, 42.1; HRMS (ESI) m/z calcd for C₃₂H₂₅ClN₂O₃S [M - H]⁻ = 551.1202, found = 551.1199; the *ee* value was 91%, t_R (major) = 10.7 min, t_R (minor) = 12.8 min (Chiralpak IE, $\lambda = 254$ nm, 20% *i*-PrOH/Hexane, flow rate = 1.0 mL/min).



Racemic 3k

Enantioenriched 3k

(2S, 3R, 4R) - 3 - (4 - fluorophenyl) - 2 - (1H - indol - 3 - yl) - 1 - (methylsulfonyl) - 4 - phenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yhold shows a start of the start of the

b]pyridine 31



Yellowish oil; isolated yield = 99%; $[a]_D^{25} = -152$ (c 0.5, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.99 – 7.88 (m, 2H), 7.56 – 7.54 (m, 1H), 7.45 – 7.43 (m, 1H), 7.35 – 7.32 (m, 2H), 7.24 – 7.22 (m, 1H), 7.14 – 7.11 (m, 1H), 7.09 – 6.97 (m, 5H), 6.89 – 6.79 (m, 5H), 5.73 (d, J = 8.1 Hz, 1H), 4.46 (d, J = 6.8 Hz, 1H), 4.38 – 4.35 (m, 1H), 2.43 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 161.7 (d, J = 245 Hz), 154.1, 146.9, 139.0, 137.4, 137.4, 135.7, 129.5 (d, J = 7 Hz), 128.2, (d, J = 13 Hz), 126.8, 126.3, 125.6, 124.7, 123.6, 123.1, 122.4, 121.2, 120.2, 118.5, 115.5 (d, J = 21 Hz), 111.9, 111.5, 111.3, 61.2, 51.7, 47.2, 42.2; HRMS (ESI) m/z calcd for C₃₂H₂₅FN₂O₃S [M - H]⁻ = 535.1497, found = 535.1500; the *ee* value was 92%, t_R (major) = 8.1 min, t_R (minor) = 13.5 min (Chiralpak IE, $\lambda = 254$ nm, 20% *i*-PrOH/Hexane, flow rate = 1.0 mL/min).



tetrahydrobenzofuro[3,2-b]pyridine 3m



Yellowish oil; isolated yield = 96%; $[a]_D^{25} = -152$ (c 0.5, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.00 (s, 1H), 7.89 – 7.87 (m, 1H), 7.57 – 7.55 (m, 1H), 7.44 – 7.42 (m, 1H), 7.35 – 7.31 (m, 2H), 7.25 – 7.23 (m, 1H), 7.18 – 6.93 (m, 8H), 6.85 – 6.83 (m, 3H), 5.71 (d, J = 8.4 Hz, 1H), 4.44 (d, J = 7.1 Hz, 1H), 4.38 – 4.35 (m, 1H), 2.42 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 154.1, 147.1, 140.1, 138.8, 135.7, 132.8, 129.4, 128.8, 128.3, 128.2, 126.9, 126.4, 125.8, 124.7, 123.8, 123.1, 122.5, 121.1, 120.3, 120.2, 118.5, 111.9, 111.5, 111.0, 61.0, 51.9, 47.4, 42.3; HRMS (ESI) m/z calcd for C₃₂H₂₅ClN₂O₃S [M - H]⁻ = 551.1202, found = 551.1192; the *ee* value was 96%, t_R (major) = 9.0 min, t_R (minor) = 15.1 min (Chiralpak IE, $\lambda = 254$ nm, 20% *i*-PrOH/Hexane, flow rate = 1.0 mL/min).



tetrahydrobenzofuro[3,2-b]pyridine 3n



Yellowish oil; isolated yield = 98%; $[a]_D^{25} = -132$ (c 1.0, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.05 (s, 1H), 7.86 – 7.84 (m, 1H), 7.60 – 7.58 (m, 1H), 7.48 – 7.38 (m, 3H), 7.35 – 7.32 (m, 2H), 7.25 (s, 1H), 7.19 – 7.03 (m, 7H), 6.90 – 6.80 (m, 2H), 5.75 (d, J = 8.1 Hz, 1H), 4.51 – 4.39 (m, 2H), 2.41 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 154.1, 147.2, 145.7, 138.6, 135.6, 129.4, 129.1, 128.4, 128.3, 128.3, 127.1, 126.5, 126.0, 125.5, 125.5, 124.7, 124.0 (q, J = 271 Hz), 123.8, 123.2, 122.6, 121.1, 120.4, 120.3, 118.4, 111.9, 111.6, 110.6, 60.7, 52.4, 47.7, 42.4; HRMS (ESI) m/z calcd for C₃₃H₂₅F₃N₂O₃S [M - H]⁻ = 585.1465, found = 585.1446; the *ee* value was 96%, t_R (major) = 6.3 min, t_R (minor) = 11.3 min (Chiralpak IE, $\lambda = 254$ nm, 20% *i*-PrOH/Hexane, flow rate = 1.0 mL/min).



(2S, 3R, 4R) - 2 - (1H-indol-3-yl) - 1 - (methylsulfonyl) - 4 - phenyl - 3 - (p-tolyl) - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2-indol-3-yl] - 1 - (methylsulfonyl) - 4 - phenyl - 3 - (p-tolyl) - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2-indol-3-yl] - 1 - (methylsulfonyl) - 4 - phenyl - 3 - (p-tolyl) - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2-indol-3-yl] - 1 - (methylsulfonyl) - 4 - phenyl - 3 - (p-tolyl) - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2-indol-3-yl] - 1 - (methylsulfonyl) - 4 - phenyl - 3 - (p-tolyl) - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2-indol-3-yl] - 1 - (methylsulfonyl) - 4 - phenyl - 3 - (p-tolyl) - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2-indol-3-yl] - 1 - (methylsulfonyl) - 4 - phenyl - 3 - (p-tolyl) - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2-indol-3-yl] - 1 - (methylsulfonyl) - 4 - phenyl - 3 - (p-tolyl) - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2-indol-3-yl] - 1 - (methylsulfonyl) - 4 - phenyl - 3 - (p-tolyl) - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2-indol-3-yl] - 1 - (methylsulfonyl) - 4 - phenyl - 3 - (p-tolyl) - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2-indol-3-yl] - 1 - (methylsulfonyl) - 4 - phenyl - 3 - (p-tolyl) - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2-indol-3-yl] - 1 - (methylsulfonyl) - 4 - phenyl - 3 - (p-tolyl) - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2-indol-3-yl] - 1 - (methylsulfonyl) - (methylsu

<u>b]pyridine</u> **30**



Yellowish oil; isolated yield = 98%; $[a]_D^{25} = -112$ (c 1.0, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 8.07 – 8.05 (m, 1H), 7.89 (s, 1H), 7.55 – 7.53 (m, 1H), 7.47 – 7.44 (m, 1H), 7.36 – 7.32 (m, 2H), 7.18 – 7.15 (m, 1H), 7.12 – 6.97 (m, 6H), 6.97 – 6.86 (m, 2H), 6.83 – 6.82 (m, 1H), 6.78 – 6.71 (m, 2H), 5.84 (d, *J* = 7.0 Hz, 1H), 4.56 (d, *J* = 5.5 Hz, 1H), 4.41 – 4.34 (m, 1H), 2.35 (s, 3H), 2.27 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 154.1, 146.3, 139.5, 138.8, 136.8, 135.9, 129.4, 128.0, 127.9, 127.8, 126.3, 126.1, 124.9, 124.6, 123.3, 123.1, 122.1, 121.5, 119.9, 118.6, 112.2, 111.8, 111.3, 61.5, 51.1, 45.6, 41.5; HRMS (ESI) m/z calcd for C₃₃H₂₈N₂O₃S [M - H]⁻ = 531.1748, found = 531.1759; the *ee* value was 92%, t_R (major) = 15.2 min, t_R (minor) = 28.1 min (Chiralpak IE, λ = 254 nm, 20% *i*-PrOH/Hexane, flow rate = 1.0 mL/min).



tetrahydrobenzofuro[3,2-b]pyridine 3p



Yellowish oil; isolated yield = 98%; $[a]_D^{25} = -138$ (c 1.0, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.05 (s, 1H), 7.84 – 7.82 (m, 1H), 7.57 – 7.55 (m, 1H), 7.44 – 7.42 (m, 1H), 7.37 – 7.26 (m, 2H), 7.23 – 7.13 (m, 2H), 7.13 – 7.05 (m, 5H), 6.91 – 6.81 (m, 4H), 5.66 (d, J = 8.6 Hz, 1H), 4.43 – 4.29 (m, 2H), 2.46 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 154.2, 147.1, 141.9, 138.5, 135.6, 132.5, 131.0, 130.6, 130.0, 128.4, 128.3, 127.4, 127.2, 126.4, 125.9, 124.7, 123.8, 123.2, 122.7, 121.0, 120.5, 120.3, 118.4, 111.9, 111.6, 110.5, 60.6, 52.1, 47.9, 42.5; HRMS (ESI) m/z calcd for C₃₂H₂₄Cl₂N₂O₃S [M - H]⁻ = 585.0812, found = 585.0804; the *ee* value was 95%, t_R (major) = 11.7 min, t_R (minor) = 12.7 min (Chiralpak ID, λ = 254 nm, 20% *i*-PrOH/Hexane, flow rate = 1.0 mL/min).



Racemic 3p

Enantioenriched 3p

tetrahydrobenzofuro[3,2-b]pyridine 3q



Brownish oil; isolated yield = 99%; $[a]_D^{25} = -139$ (c 1.0, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 7.99 – 7.92 (m, 1H), 7.90 – 7.85 (m, 1H), 7.78 – 7.65 (m, 2H), 7.64 – 7.61 (m, 2H), 7.51 – 7.31 (m, 5H), 7.35 – 7.25 (m, 1H), 7.22 – 7.15 (m, 1H), 7.15 – 7.03 (m, 2H), 7.02 – 6.94 (m, 3H), 6.87 – 6.77 (m, 3H), 5.92 (d, *J* = 8.0 Hz, 1H), 4.65 (d, *J* = 6.6 Hz, 1H), 4.59 – 4.55 (m, 1H), 2.29 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 154.1, 147.3, 139.3, 139.0, 135.7, 133.2, 132.4, 128.6, 128.2, 128.1, 127.8, 127.6, 127.1, 126.7, 126.5, 126.2, 125.9, 125.7, 124.6, 123.8, 123.1, 122.3, 121.3, 120.2, 120.1, 118.6, 111.9, 111.4, 61.2, 52.3, 46.9, 42.0; HRMS (ESI) m/z calcd for C₃₆H₂₈N₂O₃S [M - H]⁻ = 567.1748, found = 567.1752; the *ee* value was 97%, t_R (major) = 19.6 min, t_R (minor) = 25.6 min (Chiralpak IE, λ = 254 nm, 20% *i*-PrOH/Hexane, flow rate = 1.0 mL/min).



Racemic 3q

Enantioenriched 3q

(2S, 3S, 4R) - 2 - (1H - indol - 3 - yl) - 1 - (methyl sulfonyl) - 4 - phenyl - 3 - (thiophen - 2 - yl) - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yl) - 1, 2, 3, 4

<u>b]pyridine</u> 3r



Brownish oil; isolated yield = 98%; $[a]_D^{25} = -60$ (c 0.5, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 8.21 – 8.14 (m, 1H), 7.85 (s, 1H), 7.52 – 7.43 (m, 2H), 7.40 – 7.30 (m, 2H), 7.19 – 6.93 (m, 4H), 6.92 – 6.79 (m, 5H), 6.78 – 6.67 (m, 2H), 5.98 (d, J = 5.3 Hz, 1H), 4.71 – 4.68 (m, 2H), 2.45 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 154.2, 145.4, 139.2, 136.2, 127.6, 126.9, 126.2, 125.6, 124.8, 124.4, 124.1, 123.2, 122.7, 122.1, 121.7, 119.8, 119.3, 118.6, 112.4, 111.9, 111.2, 61.8, 46.7, 45.9, 41.1; HRMS (ESI) m/z calcd for C₃₀H₂₄N₂O₃S₂ [M - H]⁻ = 523.1156, found = 523.1144; the *ee* value was 65%, t_R (major) = 12.9 min, t_R (minor) = 35.9 min (Chiralpak IE, λ = 254 nm, 20% *i*-PrOH/Hexane, flow rate = 1.0 mL/min).





Enantioenriched 3r

(2S, 3R, 4R) - 4 - (2 - fluorophenyl) - 2 - (1H - indol - 3 - yl) - 1 - (methylsulfonyl) - 3 - phenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl) - 3 - phenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl] - 3 - phenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl] - 3 - phenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl] - 3 - phenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl] - 3 - phenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl] - 3 - phenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl] - 3 - phenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl] - 3 - phenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl] - 3 - phenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl] - 3 - phenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl] - 3 - phenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl] - 3 - phenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl] - 3 - phenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl] - 3 - phenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl] - 3 - phenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl] - 3 - phenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl] - 3 - phenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl] - 3 - phenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl] - 3 - phenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl] - 3 - phenyl - 1, 2, 3 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl] - 3 - phenyl - 1, 2, 3 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl] - 3 - phenyl - 1, 2, 3 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl] - 3 - phenyl -

<u>b]pyridine</u> 3s



Yellowish oil; isolated yield = 90%; $[a]_D^{25} = -117$ (c 1.0, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.24 – 8.23 (m, 1H), 7.84 (s, 1H), 7.55 – 7.46 (m, 2H), 7.41 – 7.20 (m, 6H), 7.13 – 6.93 (m, 3H), 6.83 – 6.71 (m, 2H), 6.68 – 6.60 (m, 1H), 6.48 – 6.45 (m, 1H), 6.25 (s, 1H), 5.98 (d, *J* = 5.3 Hz, 1H), 4.93 (d, *J* = 3.9 Hz, 1H), 4.53 – 4.48 (m, 1H), 2.35 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 160.5 (d, *J* = 244 Hz), 154.1, 141.6, 136.5, 129.2 (d, *J* = 4 Hz), 128.8, 127.9, 127.7, 127.7, 127.4, 126.2 (d, *J* = 13 Hz), 125.4, 124.8, 123.6, 123.3, 122.8, 122.8, 122.5, 122.0, 121.8, 120.1, 119.7, 118.6, 114.7 (d, *J* = 22 Hz), 113.3, 111.9, 111.2, 61.7, 48.6, 40.9, 37.6; HRMS (ESI) m/z calcd for C₃₂H₂₅FN₂O₃S [M - H]⁻ = 535.1497, found = 535.1487; the *ee* value was 92%, t_R (major) = 10.1 min, t_R (minor) = 18.0 min (Chiralpak IE, $\lambda = 254$ nm, 20% *i*-PrOH/Hexane, flow rate = 1.0 mL/min).



Racemic 3s

Enantioenriched 3s

tetrahydrobenzofuro[3,2-b]pyridine 3t



Yellowish oil; isolated yield = 82%; $[a]_D^{25} = -26$ (c 1.0, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.38 (s, 1H), 7.80 (s, 1H), 7.53 – 7.21 (m, 9H), 7.10 – 6.83 (m, 5H), 6.60 – 6.41 (m, 2H), 6.05 – 6.00 (m, 1H), 5.02 (s, 1H), 4.62 (s, 1H), 2.32 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 154.1, 142.0, 136.7, 133.1, 131.6, 129.2, 128.9, 127.9, 127.6, 127.0, 125.2, 125.1, 125.0, 123.4, 123.0, 122.1, 121.9, 120.3, 119.6, 118.5, 114.0, 112.4, 111.9, 111.0, 61.9, 47.1, 40.6, 39.6; HRMS (ESI) m/z calcd for C₃₂H₂₅ClN₂O₃S [M - H]⁻ = 551.1202, found = 551.1191; the *ee* value was 89%, t_R (major) = 8.7 min, t_R (minor) = 18.5 min (Chiralpak IE, λ = 254 nm, 20% *i*-PrOH/Hexane, flow rate = 1.0 mL/min).



tetrahydrobenzofuro[3,2-b]pyridine 3u



Yellowish oil; isolated yield = 84%; $[a]_D^{25} = -51$ (c 1.0, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.23 – 8.18 (m, 1H), 7.86 (s, 1H), 7.52 – 7.24 (m, 8H), 7.15 – 6.91 (m, 3H), 6.82 – 6.58 (m, 4H), 6.36 (s, 1H), 5.94 (d, *J* = 5.1 Hz, 1H), 4.59 (d, *J* = 3.6 Hz, 1H), 4.39 – 4.37 (m, 1H), 2.30 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 154.3, 143.4, 141.8, 136.4, 133.2, 129.5, 129.0, 128.9, 128.0, 127.8, 127.7, 126.2, 126.1, 125.5, 125.1, 124.1, 123.4, 122.4, 122.2, 122.0, 120.2, 119.9, 118.6, 112.8, 112.1, 111.3, 61.5, 50.3, 43.2, 41.2; HRMS (ESI) m/z calcd for C₃₂H₂₅ClN₂O₃S [M - H]⁻ = 551.1202, found = 551.1197; the *ee* value was 83%, t_R (major) = 12.0 min, t_R (minor) = 30.4 min (Chiralpak IE, λ = 254 nm, 20% *i*-PrOH/Hexane, flow rate = 1.0 mL/min).



tetrahydrobenzofuro[3,2-b]pyridine 3v



Yellowish oil; isolated yield = 80%; $[a]_D^{25} = -116$ (c 0.4, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.27 – 8.25 (m, 1H), 7.89 (s, 1H), 7.55 – 7.29 (m, 8H), 7.19 – 6.93 (m, 3H), 6.84 (s, 2H), 6.70 – 6.67 (m, 2H), 6.51 (s, 1H), 5.99 (d, *J* = 4.6 Hz, 1H), 4.63 (s, 1H), 4.42 (s, 1H), 2.34 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 154.2, 142.0, 141.7, 136.3, 130.5, 129.1, 129.0, 127.9, 127.6, 126.4, 125.3, 125.0, 123.8, 123.4, 122.1, 122.0, 121.4, 120.0, 119.8, 118.5, 112.0, 111.2, 61.4, 50.0, 42.8, 41.1; HRMS (ESI) m/z calcd for C₃₂H₂₅BrN₂O₃S [M - H]⁻ = 595.0696, found = 595.0698; the *ee* value was 89%, t_R (major) = 12.4 min, t_R (minor) = 34.5 min (Chiralpak IE, λ = 254 nm, 20% *i*-PrOH/Hexane, flow rate = 1.0 mL/min).



tetrahydrobenzofuro[3,2-b]pyridine 3w



Yellowish oil; isolated yield = 92%; $[a]_D^{25} = -93$ (c 1.0, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.29 – 8.28 (m, 1H), 7.84 (s, 1H), 7.55 – 7.24 (m, 8H), 7.09 – 6.70 (m, 8H), 6.02 (d, J = 4.7 Hz, 1H), 4.72 (d, J = 2.8 Hz, 1H), 4.48 – 4.43 (m, 1H), 2.33 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 154.2, 141.6, 140.8, 136.3, 130.8, 129.6, 129.3, 129.0, 127.9, 127.9, 127.7, 125.1, 124.1, 123.9 (q, J = 271 Hz), 123.5, 123.4, 122.7, 122.1, 122.0, 120.2, 119.7, 118.4, 112.8, 111.9, 111.3, 61.4, 49.9, 42.7, 41.0; HRMS (ESI) m/z calcd for C₃₃H₂₅F₃N₂O₃S [M - H]⁻ = 585.1465, found = 585.1470; the *ee* value was 90%, t_R (major) = 8.1 min, t_R (minor) = 19.2 min (Chiralpak IE, $\lambda = 254$ nm, 20% *i*-PrOH/Hexane, flow rate = 1.0 mL/min).



(2S, 3R, 4R) - 4 - (4 - fluorophenyl) - 2 - (1H - indol - 3 - yl) - 1 - (methylsulfonyl) - 3 - phenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl) - 3 - phenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl) - 3 - phenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl) - 3 - phenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl) - 3 - phenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl) - 3 - phenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl) - 3 - phenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl) - 3 - phenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl] - 3 - phenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl] - 3 - phenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl] - 3 - phenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl] - 3 - phenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl] - 3 - phenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl] - 3 - phenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl] - 3 - phenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl] - 3 - phenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl] - 3 - phenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl] - 3 - phenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl] - 3 - phenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl] - 3 - phenyl - 1, 2, 3, 4 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl] - 3 - phenyl - 1, 2, 3 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl] - 3 - phenyl - 1, 2, 3 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl] - 3 - phenyl - 1, 2, 3 - tetrahydrobenzofuro [3, 2 - yhold methylsulfonyl] - 3 - phenyl -

<u>b]pyridine 3x</u>



Yellowish oil; isolated yield = 93%; $[a]_D^{25} = -113$ (c 1.0, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.10 – 8.04 (m, 1H), 7.93 (s, 1H), 7.56 – 7.32 (m, 6H), 7.25 – 7.14 (m, 9H), 7.14 – 7.00 (m, 4H), 6.82 – 6.81 (m,1H), 6.72 – 6.56 (m, 5H), 5.88 (d, *J* = 6.8 Hz, 1H), 4.57 (d, *J* = 5.4 Hz, 1H), 4.41 – 4.35 (m, 1H), 2.33 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 161.3 (d, *J* = 244 Hz), 154.1, 145.7, 141.6, 136.0, 135.2 (d, *J* = 3 Hz), 129.4 (d, *J* = 8 Hz), 128.8, 128.0, 127.3, 126.0, 124.8, 123.2, 123.1, 122.3, 121.6, 120.1, 112.0, 118.5, 114.6 (d, *J* = 22 Hz), 112.0, 111.8, 111.4, 61.4, 51.4, 44.7, 41.5; HRMS (ESI) m/z calcd for C₃₂H₂₅FN₂O₃S [M - H]⁻ = 535.1497, found = 535.1492; the *ee* value was 95%, t_R (major) = 10.4 min, t_R (minor) = 20.3 min (Chiralpak IE, λ = 254 nm, 20% *i*-PrOH/Hexane, flow rate = 1.0 mL/min).



Racemic 3x

Enantioenriched 3x

tetrahydrobenzofuro[3,2-b]pyridine 3y



Yellowish oil; isolated yield = 83%; $[a]_D^{25} = -50$ (c 1.0, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 8.10 – 8.08 (m, 1H), 7.90 (s, 1H), 7.59 – 7.31 (m, 4H), 7.28 – 6.99 (m, 7H), 6.86 – 6.84 (m, 3H), 6.64 – 6.62 (m, 2H), 5.89 (d, J = 6.5 Hz, 1H), 4.57 (d, J = 4.9 Hz, 1H), 4.40 – 4.37 (m,1H), 2.32 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 154.1, 141.6, 138.0, 136.0, 132.1, 129.1, 128.8, 128.3, 128.0, 127.9, 127.4, 125.9, 125.4, 124.9, 124.7, 123.3, 123.0, 122.4, 121.7, 120.2, 120.0, 118.6, 111.8, 111.4, 61.4, 53.5, 51.0, 41.5; HRMS (ESI) m/z calcd for C₃₂H₂₅ClN₂O₃S [M - H]⁻ = 551.1202, found = 551.1204; the *ee* value was 91%, t_R (major) = 11.7 min, t_R (minor) = 22.0 min (Chiralpak IE, $\lambda = 254$ nm, 20% *i*-PrOH/Hexane, flow rate = 1.0 mL/min).



Racemic 3y

Enantioenriched 3y

tetrahydrobenzofuro[3,2-b]pyridine 3z



Yellowish oil; isolated yield = 80%; $[a]_D^{25} = -160$ (c 0.5, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.11 – 8.09 (m, 1H), 7.88 (s, 1H), 7.54 – 7.44 (m, 2H), 7.40 – 7.31 (m, 2H), 7.31 – 7.15 (m, 5H), 7.13 – 7.10 (m, 1H), 7.05 – 6.95 (m, 3H), 6.84 – 6.80 (m, 1H), 6.57 – 6.55 (m, 2H), 5.90 (d, *J* = 6.6 Hz, 1H), 4.55 (d, *J* = 5.0 Hz, 1H), 4.40 – 4.38 (m, 1H), 2.31 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 154.1, 141.5, 138.6, 136.1, 130.8, 129.5, 128.9, 128.0, 127.4, 124.9, 124.6, 123.3, 122.9, 122.4, 121.7, 120.2, 120.0, 118.5, 112.2, 111.8, 111.5, 61.4, 50.8, 44.4, 41.5; HRMS (ESI) m/z calcd for C₃₂H₂₅BrN₂O₃S [M - H]⁻ = 595.0696, found = 595.0685; the *ee* value was 89%, t_R (major) = 11.5 min, t_R (minor) = 20.8 min (Chiralpak IE, λ = 254 nm, 20% *i*-PrOH/Hexane, flow rate = 1.0 mL/min).



tetrahydrobenzofuro[3,2-b]pyridine 3a'



Yellowish oil; isolated yield = 90%; $[a]_D^{25} = -75$ (c 0.5, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.34 – 8.28 (m, 1H), 7.81 (s, 1H), 7.53 – 7.47 (m, 2H), 7.43 – 7.20 (m, 6H), 7.12 – 6.97 (m, 3H), 6.85 – 6.68 (m, 2H), 6.31 – 6.28 (m, 1H), 6.06 – 5.90 (m, 2H), 4.92 (d, *J* = 3.1 Hz, 1H), 4.58 – 4.53 (m, 1H), 2.31 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 155.8 (d, *J* = 247 Hz), 154.2, 141.4, 136.7, 129.0, 128.1, 128.0, 127.8, 127.6 (d, *J* = 4 Hz), 125.2, 123.6, 123.4, 123.0 (d, *J* = 5 Hz), 122.2 (d, *J* = 8 Hz), 120.3, 119.9, 118.6, 113.7, 112.0, 111.2, 61.8, 47.5, 40.8, 37.2; HRMS (ESI) m/z calcd for C₃₂H₂₄ClFN₂O₃S [M - H]⁻ = 569.1107, found = 569.1105; the *ee* value was 97%, t_R (major) = 10.1 min, t_R (minor) = 23.8 min (Chiralpak IE, λ = 254 nm, 20% *i*-PrOH/Hexane, flow rate = 1.0 mL/min).



Racemic 3a'

Enantioenriched 3a'

(2S,3R,4R)-2-(1H-indol-3-yl)-1-(methylsulfonyl)-4-(naphthalen-2-yl)-3-phenyl-1,2,3,4-

tetrahydrobenzofuro[3,2-b]pyridine 3b'



Yellowish oil; isolated yield = 85%; $[a]_D^{25} = -135$ (c 1.0, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.10 – 8.04 (m, 1H), 7.81 (s, 1H), 7.64 – 7.51 (m, 2H), 7.48 – 7.29 (m, 6H), 7.21 – 7.17 (m, 5H), 7.07 (s, 1H), 7.03 – 6.85 (m, 5H), 5.90 (d, J = 7.1 Hz, 1H), 4.74 (d, J = 5.6 Hz, 1H), 4.56 – 4.50 (m, 1H), 2.37 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 154.1, 141.8, 136.8, 135.8, 133.0, 132.2, 128.7, 128.1, 127.8, 127.6, 127.4, 127.2, 127.2, 126.1, 125.9, 125.7, 125.4, 125.1, 124.6, 123.4, 123.2, 122.14 121.5, 120.1, 119.9, 118.5, 111.9, 111.1, 61.5, 51.1, 46.0, 41.7; HRMS (ESI) m/z calcd for C₃₆H₂₈N₂O₃S [M - H]⁻ = 567.1748, found = 567.1754; the *ee* value was 87%, t_R (major) = 15.3 min, t_R (minor) = 34.1 min (Chiralpak IE, $\lambda = 254$ nm, 20% *i*-PrOH/Hexane, flow rate = 1.0 mL/min).



Racemic 3b'

Enantioenriched 3b'



Yellowish oil; isolated yield = 95%; $[a]_D^{25}$ = +75 (c 1.0, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.34 (s, 1H), 7.58 - 7.56 (m, 1H), 7.49 - 7.34 (m, 4H), 7.34 - 7.14 (m, 13H), 7.02 - 6.99 (m, 1H), 6.83 (d, *J* = 16.3 Hz, 1H), 6.49 (s, 1H), 6.09 (d, *J* = 13.3 Hz, 1H), 2.87 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 156.2, 153.3, 139.9, 136.7, 136.6, 133.8, 128.9, 128.6, 128.5, 128.3, 127.9, 127.9, 127.0, 126.5, 125.8, 124.8, 123.6, 123.4, 120.6, 120.2, 118.7, 117.0, 114.2, 113.5, 112.2, 110.7, 40.3, 38.9; HRMS (ESI) m/z calcd for C₃₂H₂₆N₂O₃S [M - H]⁻ = 517.1591, found = 517.1590; the *ee* value was 92%, t_R (major) = 5.2 min, t_R (minor) = 6.0 min (Chiralpak IC, λ = 254 nm, 20% *i*-PrOH/Hexane, flow rate = 1.0 mL/min).



Racemic 5

Enantioenriched 5



Off white oil; isolated yield = 96%; $[a]_D^{25} = -35.5$ (c 1.0, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 8.30 – 8.20 (m, 1H), 7.88 – 7.86 (m, 1H), 7.57 – 7.06 (m, 12H), 6.82 – 6.79 (m, 3H), 6.71 – 6.61 (m, 2H), 5.92 – 5.91 (m, 1H), 4.71 (d, *J* = 3.6 Hz, 1H), 4.35 – 4.32 (m, 1H), 2.41 (s, 3H), 1.53 (s, 9H); ¹³C NMR (126 MHz, CDCl₃) δ 154.10, 149.27, 143.98, 141.49, 139.22, 135.47, 128.94, 128.37, 128.02, 127.99, 127.69, 127.63, 127.41, 126.12, 126.08, 125.15, 124.88, 124.77, 124.21, 123.34, 122.40, 122.21, 121.80, 119.60, 118.75, 117.55, 115.19, 111.77, 83.61, 60.83, 50.27, 42.69, 40.71, 28.03, 27.95, 27.72; HRMS (ESI) m/z calcd for C₃₇H₃₅N₂O₅S [M + H]⁺ = 619.2261, found = 619.2278; the *ee* value was 90%, t_R (major) = 20.5 min, t_R (minor) = 34.4 min (Chiralpak IE, λ = 254 nm, 20% *i*-PrOH/Hexane, flow rate = 0.5 mL/min).




Pale yellow oil; isolated yield = 93%; $[a]_D^{25} = -33.8$ (c 1.0, MeOH); ¹H NMR (400 MHz, CD₃CN) δ 8.68 (s, 1H), 7.63 – 7.53 (m, 2H), 7.36 (d, J = 7.8 Hz, 1H), 7.32 – 7.21 (m, 5H), 7.19 – 7.14 (m, 1H), 7.04 – 6.90 (m, 9H), 6.40 (d, J = 2.2 Hz, 1H), 4.81 (d, J = 11.4 Hz, 1H), 3.92 (td, J = 11.4, 3.3 Hz, 1H), 3.02 (dd, J = 14.5, 11.4 Hz, 1H), 2.90 – 2.82 (m, 4H); ¹³C NMR (100 MHz, CD₃CN) δ 156.9, 153.8, 143.4, 140.7, 136.7, 129.4, 129.3, 128.6, 128.3, 127.9, 127.1, 126.6, 125.3, 124.0, 123.2, 121.7, 119.9, 119.2, 118.8, 115.2, 113.6, 112.0, 111.7, 51.3, 49.0, 40.5, 31.1; HRMS (ESI) m/z calcd for C₃₂H₂₇N₂O₃S [M - H]⁻ = 519.1748, found = 519.1760; the *ee* value was 89%, t_R (major) = 16.4 min, t_R (minor) = 11.1 min (Chiralpak AD-H, $\lambda = 254$ nm, 20% *i*-PrOH/Hexane, flow rate = 1.0 mL/min).



D. X-Ray Crystallographic Analysis and Determination of the Absolute Configurations of Product 3b



Figure 1. X-ray structure of **3b** (CCDC 2027692)

Table 1. Crystal data and structure refinement for K Identification code	255. K255	
Empirical formula	C35 H32 F N2 O3 S	
Formula weight	579.68	
Temperature	100(2) K	
Wavelength	0.71073 Å	
Crystal system	Orthorhombic	
Space group	P212121	
Unit cell dimensions	a = 10.8396(7) Å	a= 90°.
	b = 14.8000(10) Å	b= 90°.
	c = 20.0419(13) Å	g = 90°.
Volume	3215.2(4) Å ³	
Z	4	
Density (calculated)	1.198 Mg/m ³	

Absorption coefficient

0.142 mm⁻¹

F(000)	1220
Crystal size	0.340 x 0.272 x 0.051 mm ³
Theta range for data collection	2.753 to 29.756°.
Index ranges	-15<=h<=15, -20<=k<=20, -25<=l<=27
Reflections collected	46293
Independent reflections	9075 [R(int) = 0.0911]
Completeness to theta = 25.242°	99.7 %
Absorption correction	Semi-empirical from equivalents
Max. and min. transmission	0.7459 and 0.5968
Refinement method	Full-matrix least-squares on F ²
Data / restraints / parameters	9075 / 49 / 409
Goodness-of-fit on F ²	1.066
Final R indices [I>2sigma(I)]	R1 = 0.0703, wR2 = 0.1644
R indices (all data)	R1 = 0.1416, wR2 = 0.2051
Absolute structure parameter	-0.03(5)
Extinction coefficient	0.025(3)
Largest diff. peak and hole	0.730 and -0.534 e.Å ⁻³

E. References

[1] H. Ni, X. Tang, W. Zheng, W. Yao, N. Ullah and Y. Lu, Angew. Chem. Int. Ed., 2017, 56, 14222-14226.

[2] X.-K. Guan, G.-F. Liu, D. An, H. Zhang and S.-Q. Zhang, Org. Lett., 2019, 21, 5438-5422.

F. ¹H and ¹³C NMR Spectra of Products





































































HSQC



